Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.32 |
| ▸ | IDO1 | P14902 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5020152 | 0.78 | MAP4K4 (0.47) | — | |
| SCHEMBL1822901 | 0.78 | NOTUM (0.33) | NOTUMIDO1 | |
| SCHEMBL5020277 | 0.78 | IDO1 (0.46) | NOTUMIDO1 | |
| SCHEMBL30171029 | 0.78 | IDO1 (0.54) | NOTUMIDO1 | |
| SCHEMBL5020151 | 0.78 | IDO1 (0.46) | IDO1 | |
| SCHEMBL5020146 | 0.78 | HSD17B1 (0.48) | — | |
| SCHEMBL5020148 | 0.78 | METAP2 (0.46) | NOTUMIDO1 | |
| SCHEMBL5020244 | 0.77 | SCN2A (0.56) | NOTUMSCN2AIDO1 | |
| SCHEMBL10018 | 0.76 | SCN4A (0.46) | SCN2AIDO1 | |
| SCHEMBL23150465 | 0.74 | IDO1 (0.40) | NOTUMIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129886-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129886-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | NOTUM 1126/4885SCN2A 2330/4885IDO1 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.